1. A Self-Driven Bioreactor Based on Bacterium–Metal–Organic Framework Biohybrids for Boosting Chemotherapy via Cyclic Lactate Catabolism
- Author
-
Juan Yang, Xian-Zheng Zhang, Wen-Fang Song, Zi-Yi Han, Qi-Wen Chen, Guo-Feng Luo, Wei-Hai Chen, and Jia-Wei Wang
- Subjects
medicine.medical_treatment ,General Physics and Astronomy ,Shewanella ,Bioreactors ,Neoplasms ,Tumor Microenvironment ,Bioreactor ,medicine ,Humans ,General Materials Science ,Self driven ,Metal-Organic Frameworks ,Boosting (doping) ,Tumor microenvironment ,Chemotherapy ,biology ,Chemistry ,Lactate catabolism ,General Engineering ,equipment and supplies ,biology.organism_classification ,Doxorubicin ,Lactates ,Cancer research ,Nanoparticles ,Bacteria - Abstract
The excessive lactate in the tumor microenvironment always leads to poor therapeutic outcomes of chemotherapy. In this study, a self-driven bioreactor (defined as SO@MDH, where SO isiShewanella oneidensis/iMR-1 and MDH is MIL-101 metal-organic framework nanoparticles/doxorubicin/hyaluronic acid) is rationally constructedivia/ithe integration of doxorubicin (DOX)-loaded metal-organic framework (MOF) MIL-101 nanoparticles with SO to sensitize chemotherapy. Owing to the intrinsic tumor tropism and electron-driven respiration of SO, the biohybrid SO@MDH could actively target and colonize hypoxic and eutrophic tumor regions and anaerobically metabolize lactate accompanied by the transfer of electrons to Fesup3+/sup, which is the key component of the MIL-101 nanoparticles. As a result, the intratumoral lactate would undergo continuous catabolism coupled with the reduction of Fesup3+/supto Fesup2+/supand the subsequent degradation of MIL-101 frameworks, leading to an expeditious drug release for effective chemotherapy. Meanwhile, the generated Fesup2+/supwill be promptly oxidized by the abundant hydrogen peroxide in the tumor microenvironment to reproduce Fesup3+/sup, which is, in turn, beneficial to circularly catabolize lactate and boost chemotherapy. More importantly, the consumption of intratumoral lactic acid could significantly inhibit the expression of multidrug resistance-related ABCB1 protein (also named P-glycoprotein (P-gp)) for conquering drug-resistant tumors. SO@MDH demonstrated here holds high tumor specificity and promising chemotherapeutic efficacy for suppressing tumor growth and overcoming multidrug resistance, confirming its potential prospects in cancer therapy.
- Published
- 2021